المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/Additional_information_on_methods_/25277619

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s003
https://figshare.com/articles/journal_contribution/Additional_information_on_methods_/25277619

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/CONSORT_checklist_/25277616

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s002
https://figshare.com/articles/journal_contribution/CONSORT_checklist_/25277616

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/Study_protocol_/25277613

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s001
https://figshare.com/articles/journal_contribution/Study_protocol_/25277613

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/Model_of_follow-up_telephone_interviews_/25277622

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s004
https://figshare.com/articles/journal_contribution/Model_of_follow-up_telephone_interviews_/25277622

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/Adverse_Events_at_day_28_/25277637

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s008
https://figshare.com/articles/journal_contribution/Adverse_Events_at_day_28_/25277637

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/Viral_load_measurements_with_available_results_in_each_group_/25277628

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s005
https://figshare.com/articles/journal_contribution/Viral_load_measurements_with_available_results_in_each_group_/25277628

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/Additional_data_on_baseline_characteristics_/25277631

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s006
https://figshare.com/articles/journal_contribution/Additional_data_on_baseline_characteristics_/25277631

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/Symptoms-free_days_up_to_day_10_/25277643

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s010
https://figshare.com/articles/journal_contribution/Symptoms-free_days_up_to_day_10_/25277643

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/Sensitivity_analysis_for_the_primary_outcome_/25277646

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s011
https://figshare.com/articles/journal_contribution/Sensitivity_analysis_for_the_primary_outcome_/25277646

المؤلفون: Bruno Martins Tomazini, Lucas Tramujas, Fernando Azevedo Medrado Junior, Samara Pinheiro do Carmo Gomes, Karina Leal Negrelli, Gabriela Souza Murinize, Renato Hideo Nakagawa Santos, Bruna Martins Pereira Vianna, Bruna Fornazieri Piotto, Thabata Silva Veiga, Bianca Rodrigues do Santos, Ana Clara Peneluppi Horak, Olivia Mora Cavalcante Lemos, Marcela de Almeida Lopes, Beatriz Baptista Olicheski, Diego Lurentt Campones, Luiz Angelo Alencar Peixoto, Aline dos Anjos Chaves Basilio, Otavio Celso Eluf Gebara, Ana Tarina Alvarez Lopes, Humberto Saconato, Nanci Valeis, Tamiris Abait Miranda, Ligia Nasi Laranjeira, Eliana Vieira Santucci, Aaron Foster Carlin, Jeffrey David Esko, Phillip Leo Stephan Marie Gordts, Sotirios Tsimikas, Alexandre Biasi Cavalcanti

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Biotechnology, Evolutionary Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, trna synthetase inhibitor, symptomatic (&# 8804, serious adverse events, within 10 days, statistically significant difference, mean decay rate, hospitalized adult patients, receive halofuginone 0, 19 halofuginone treatment, halofuginone 1mg group, decay rate, 10 days, mean difference, hospitalized adults, halofuginone 1mg, halofuginone 0, placebo group, %22">xlink ">, well tolerated, vitro <

Relation: https://figshare.com/articles/journal_contribution/Post-hoc_analysis_/25277649

الاتاحة: https://doi.org/10.1371/journal.pone.0299197.s012
https://figshare.com/articles/journal_contribution/Post-hoc_analysis_/25277649

المؤلفون: Sara Sakowitz, Syed Shahyan Bakhtiyar, Konmal Ali, Saad Mallick, Catherine Williamson, Peyman Benharash

مصطلحات موضوعية: Medicine, Cell Biology, Biotechnology, Developmental Biology, Cancer, Science Policy, Infectious Diseases, Computational Biology, statistically significant difference, fourth leading cause, congenital heart disease, 92 &# 8211, 69 &# 8211, 54 &# 8211, 160 &# 8211, 06 &# 8211, 04 &# 8211, surgical resection remains, demonstrate inferior clinical, following risk adjustment, perioperative management guidelines, 2012 &# 8211, undergoing cancer resection, ci +$ 4, undergoing lobectomy, surgical management, ci 4, characterize clinical, +$ 11, risk stratification

Relation: https://figshare.com/articles/journal_contribution/ICD-9_10-CM_codes_/24928394

الاتاحة: https://doi.org/10.1371/journal.pone.0295767.s001
https://figshare.com/articles/journal_contribution/ICD-9_10-CM_codes_/24928394

المؤلفون: Bo Wang, Ryan T. Wallace, John A. Musser, Craig J. Chaya, Courtney L. Kraus

مصطلحات موضوعية: Medicine, Microbiology, Cell Biology, Biotechnology, Developmental Biology, Science Policy, Infectious Diseases, survival analysis unveiled, statistically significant difference, continuous wave cyclophotocoagulation, 2 separate institutions, long term efficacy, micropulse cyclophotocoagulation compared, term iop control, mpcpc group compared, achieving long, cwcpc group, %22">xlink ">, underwent mpcpc, two groups, intraocular pressure, favorable post, additional studies, 30 eyes, 3 %), 1 year

Relation: https://figshare.com/articles/journal_contribution/S1_File_-/24928656

الاتاحة: https://doi.org/10.1371/journal.pone.0291247.s001
https://figshare.com/articles/journal_contribution/S1_File_-/24928656

المؤلفون: Hong Duo, Mengying Jin, Yanwei Yang, Rewaan Baheti, Yujia Feng, Zirui Fu, Yuyue Jiang, Lanzhuoying Zheng, Jing Wan, Huaqin Pan

مصطلحات موضوعية: Medicine, Cell Biology, Cancer, Science Policy, Infectious Diseases, +based%22">xlink "> based, +according%22">xlink "> according, cochrane central register, 09 – 3, statistically significant difference, randomized clinical trials, 83 – 1, may predispose patients, enough evidence available, received antiplatelet therapy, antiplatelet agents exhibited, sequential analysis suggests, 2 , antiplatelet therapy, antiplatelet agents, significant benefit, sequential analysis, controlled trials, antiplatelet treatments, rr 1, february 1, used random, upper bound, thrombotic disease, systematic review

Relation: https://figshare.com/articles/journal_contribution/PRISMA_2020_checklist_/25129276

الاتاحة: https://doi.org/10.1371/journal.pone.0297628.s001
https://figshare.com/articles/journal_contribution/PRISMA_2020_checklist_/25129276

المؤلفون: Hong Duo, Mengying Jin, Yanwei Yang, Rewaan Baheti, Yujia Feng, Zirui Fu, Yuyue Jiang, Lanzhuoying Zheng, Jing Wan, Huaqin Pan

مصطلحات موضوعية: Medicine, Cell Biology, Cancer, Science Policy, Infectious Diseases, +based%22">xlink "> based, +according%22">xlink "> according, cochrane central register, 09 – 3, statistically significant difference, randomized clinical trials, 83 – 1, may predispose patients, enough evidence available, received antiplatelet therapy, antiplatelet agents exhibited, sequential analysis suggests, 2 , antiplatelet therapy, antiplatelet agents, significant benefit, sequential analysis, controlled trials, antiplatelet treatments, rr 1, february 1, used random, upper bound, thrombotic disease, systematic review

Relation: https://figshare.com/articles/journal_contribution/Description_of_primary_outcome_and_secondary_outcomes_of_meta-analysis_/25129318

الاتاحة: https://doi.org/10.1371/journal.pone.0297628.s014
https://figshare.com/articles/journal_contribution/Description_of_primary_outcome_and_secondary_outcomes_of_meta-analysis_/25129318

المؤلفون: Hong Duo, Mengying Jin, Yanwei Yang, Rewaan Baheti, Yujia Feng, Zirui Fu, Yuyue Jiang, Lanzhuoying Zheng, Jing Wan, Huaqin Pan

مصطلحات موضوعية: Medicine, Cell Biology, Cancer, Science Policy, Infectious Diseases, +based%22">xlink "> based, +according%22">xlink "> according, cochrane central register, 09 – 3, statistically significant difference, randomized clinical trials, 83 – 1, may predispose patients, enough evidence available, received antiplatelet therapy, antiplatelet agents exhibited, sequential analysis suggests, 2 , antiplatelet therapy, antiplatelet agents, significant benefit, sequential analysis, controlled trials, antiplatelet treatments, rr 1, february 1, used random, upper bound, thrombotic disease, systematic review

Relation: https://figshare.com/articles/journal_contribution/Search_strategies_/25129306

الاتاحة: https://doi.org/10.1371/journal.pone.0297628.s011
https://figshare.com/articles/journal_contribution/Search_strategies_/25129306

المؤلفون: Hong Duo, Mengying Jin, Yanwei Yang, Rewaan Baheti, Yujia Feng, Zirui Fu, Yuyue Jiang, Lanzhuoying Zheng, Jing Wan, Huaqin Pan

مصطلحات موضوعية: Medicine, Cell Biology, Cancer, Science Policy, Infectious Diseases, +based%22">xlink "> based, +according%22">xlink "> according, cochrane central register, 09 – 3, statistically significant difference, randomized clinical trials, 83 – 1, may predispose patients, enough evidence available, received antiplatelet therapy, antiplatelet agents exhibited, sequential analysis suggests, 2 , antiplatelet therapy, antiplatelet agents, significant benefit, sequential analysis, controlled trials, antiplatelet treatments, rr 1, february 1, used random, upper bound, thrombotic disease, systematic review

Relation: https://figshare.com/articles/journal_contribution/Patient_baseline_characteristics_/25129315

الاتاحة: https://doi.org/10.1371/journal.pone.0297628.s013
https://figshare.com/articles/journal_contribution/Patient_baseline_characteristics_/25129315

المؤلفون: Hong Duo, Mengying Jin, Yanwei Yang, Rewaan Baheti, Yujia Feng, Zirui Fu, Yuyue Jiang, Lanzhuoying Zheng, Jing Wan, Huaqin Pan

مصطلحات موضوعية: Medicine, Cell Biology, Cancer, Science Policy, Infectious Diseases, +based%22">xlink "> based, +according%22">xlink "> according, cochrane central register, 09 – 3, statistically significant difference, randomized clinical trials, 83 – 1, may predispose patients, enough evidence available, received antiplatelet therapy, antiplatelet agents exhibited, sequential analysis suggests, 2 , antiplatelet therapy, antiplatelet agents, significant benefit, sequential analysis, controlled trials, antiplatelet treatments, rr 1, february 1, used random, upper bound, thrombotic disease, systematic review

Relation: https://figshare.com/articles/journal_contribution/PICOs_criteria_for_inclusion_and_exclusion_of_studies_/25129312

الاتاحة: https://doi.org/10.1371/journal.pone.0297628.s012
https://figshare.com/articles/journal_contribution/PICOs_criteria_for_inclusion_and_exclusion_of_studies_/25129312

المؤلفون: Hong Duo, Mengying Jin, Yanwei Yang, Rewaan Baheti, Yujia Feng, Zirui Fu, Yuyue Jiang, Lanzhuoying Zheng, Jing Wan, Huaqin Pan

مصطلحات موضوعية: Medicine, Cell Biology, Cancer, Science Policy, Infectious Diseases, +based%22">xlink "> based, +according%22">xlink "> according, cochrane central register, 09 – 3, statistically significant difference, randomized clinical trials, 83 – 1, may predispose patients, enough evidence available, received antiplatelet therapy, antiplatelet agents exhibited, sequential analysis suggests, 2 , antiplatelet therapy, antiplatelet agents, significant benefit, sequential analysis, controlled trials, antiplatelet treatments, rr 1, february 1, used random, upper bound, thrombotic disease, systematic review

Relation: https://figshare.com/articles/journal_contribution/Description_of_primary_outcome_and_secondary_outcomes_of_meta-analysis_for_aspirin_vs_P2Y12_inhibitor_/25129321

الاتاحة: https://doi.org/10.1371/journal.pone.0297628.s015
https://figshare.com/articles/journal_contribution/Description_of_primary_outcome_and_secondary_outcomes_of_meta-analysis_for_aspirin_vs_P2Y12_inhibitor_/25129321

المؤلفون: Hong Duo, Mengying Jin, Yanwei Yang, Rewaan Baheti, Yujia Feng, Zirui Fu, Yuyue Jiang, Lanzhuoying Zheng, Jing Wan, Huaqin Pan

مصطلحات موضوعية: Medicine, Cell Biology, Cancer, Science Policy, Infectious Diseases, +based%22">xlink "> based, +according%22">xlink "> according, cochrane central register, 09 – 3, statistically significant difference, randomized clinical trials, 83 – 1, may predispose patients, enough evidence available, received antiplatelet therapy, antiplatelet agents exhibited, sequential analysis suggests, 2 , antiplatelet therapy, antiplatelet agents, significant benefit, sequential analysis, controlled trials, antiplatelet treatments, rr 1, february 1, used random, upper bound, thrombotic disease, systematic review

Relation: https://figshare.com/articles/journal_contribution/Comprehensive_overview_of_included_trials_/25129324

الاتاحة: https://doi.org/10.1371/journal.pone.0297628.s016
https://figshare.com/articles/journal_contribution/Comprehensive_overview_of_included_trials_/25129324

المؤلفون: Hong Duo, Mengying Jin, Yanwei Yang, Rewaan Baheti, Yujia Feng, Zirui Fu, Yuyue Jiang, Lanzhuoying Zheng, Jing Wan, Huaqin Pan

مصطلحات موضوعية: Medicine, Cell Biology, Cancer, Science Policy, Infectious Diseases, +based%22">xlink "> based, +according%22">xlink "> according, cochrane central register, 09 – 3, statistically significant difference, randomized clinical trials, 83 – 1, may predispose patients, enough evidence available, received antiplatelet therapy, antiplatelet agents exhibited, sequential analysis suggests, 2 , antiplatelet therapy, antiplatelet agents, significant benefit, sequential analysis, controlled trials, antiplatelet treatments, rr 1, february 1, used random, upper bound, thrombotic disease, systematic review

Relation: https://figshare.com/articles/journal_contribution/Quality_assessment_of_included_studies_by_risk_of_bias_2_0_/25129327

الاتاحة: https://doi.org/10.1371/journal.pone.0297628.s017
https://figshare.com/articles/journal_contribution/Quality_assessment_of_included_studies_by_risk_of_bias_2_0_/25129327